PDRN Injections Improved Tennis Elbow Outcomes

A recent clinical trial found that PDRN injections combined with therapy led to better functional outcomes for patients.

Updated on Sept. 28, 2026 in Arthritis

Bold vector editorial illustration of a stylized anatomical elbow junction, in teal and coral, representing clinical medical research. — A recent clinical trial found that patients with chronic tennis elbow experienced greater functional improvements when treated with PDRN injections combined with physical therapy. AI Illustration. Upload story photo >

Live Poll

Should regenerative injections like PDRN be a standard treatment for chronic tendon injuries?

Researchers have found that patients with chronic lateral epicondylitis, commonly known as tennis elbow, experienced greater improvements when treated with PDRN injections alongside physical therapy. The study compared these results against a control group receiving saline injections over a 12-week period.

Why it matters

This study explored whether adding PDRN, a regenerative agent, to standard rehabilitation protocols could enhance recovery for chronic tendon conditions. The findings suggest a potential benefit for managing pain and functional performance in patients resistant to conventional therapy alone.

In a randomized controlled trial of 48 patients, those receiving 5.625 mg of PDRN in a 3 mL injection showed statistically significant improvements in Mayo elbow performance scores and grip strength compared to the saline control group.

The players

ClinicalTrials.gov

This is a web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies.

The details

Patients were randomly assigned to receive either a PDRN or saline injection at the origin of the common extensor tendon, with both groups also undergoing extracorporeal shockwave therapy and strengthening exercises. Clinical success was measured through pain scores, tendon depth, and hand grip strength index at intervals of 6 and 12 weeks.

The clinical trial was registered on February 12, 2024.
Initial evaluation occurred at baseline.
Intermediate assessment was conducted at 6 weeks.
Final evaluation was performed at 12 weeks.

The Big Picture

This study follows the reporting and documentation standards established by the ClinicalTrials.gov registry to ensure trial transparency.

Patients suffering from chronic lateral epicondylitis may see new treatment options emerging from the use of PDRN as an adjunct to standard therapy. Individuals should consult with their healthcare provider to determine if regenerative injection therapies are appropriate for their specific case.

The takeaway

The study highlights that injectable therapies can offer superior functional gains when combined with traditional exercise and shockwave treatments. Patients should prioritize consistent physical therapy protocols while discussing emerging injection options with their specialists.